Tudor Investment Corp’s iTeos Therapeutics ITOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-15,415
Closed -$154K 3610
2025
Q2
$154K Sell
15,415
-2,236
-13% -$18K ﹤0.01% 3129
2025
Q1
$105K Buy
+17,651
New +$130K ﹤0.01% 2939
2024
Q4
Sell
-11,649
Closed -$119K 3261
2024
Q3
$119K Buy
+11,649
New +$178K ﹤0.01% 2583
2024
Q2
Sell
-17,635
Closed -$241K 2545
2024
Q1
$241K Hold
17,635
﹤0.01% 1952
2023
Q4
$193K Hold
17,635
﹤0.01% 2210
2023
Q3
$193K Buy
17,635
+3
+0% +$38 ﹤0.01% 2101
2023
Q2
$233K Sell
17,632
-40
-0.2% -$570 ﹤0.01% 2145
2023
Q1
$241K Sell
17,672
-58
-0.3% -$1.04K ﹤0.01% 2073
2022
Q4
$346K Buy
+17,730
New +$346K 0.01% 1810
2021
Q3
Sell
-25,485
Closed -$654K 2626
2021
Q2
$654K Buy
+25,485
New +$607K 0.01% 1062

Other funds holding ITOS

Tudor Investment Corp's ITOS Position: Q3 2025 in Review

Tudor Investment Corp sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 15,415 shares — an estimated $154K sold.

Tudor Investment Corp first reported a position in ITOS in Q2 2021 and held it in 10 quarters. The position peaked at $654K in Q2 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Tudor Investment Corp reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tudor Investment Corp sold 15,415 iTeos Therapeutics shares in Q3 2025, an estimated $154K.
  • Tudor Investment Corp first reported a position in iTeos Therapeutics in Q2 2021 and held it in 10 quarters.
  • Tudor Investment Corp's iTeos Therapeutics position peaked at $654K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.